Biodexa Pharmaceuticals annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Revenue Growth & History (BDRX)
Biodexa Pharmaceuticals reported £0 in revenue for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £0 | £0 | — |
| 2024 | 2024-12-31 | £0 | −£381,000 | −100.00% |
| 2023 | 2023-12-31 | £381,000 | −£318,000 | −45.49% |
| 2022 | 2022-12-31 | £699,000 | £121,000 | +20.93% |
| 2021 | 2021-12-31 | £578,000 | £235,000 | +68.51% |
| 2020 | 2020-12-31 | £343,000 | −£331,000 | −49.11% |
| 2019 | 2019-12-31 | £674,000 | −£1.3M | −65.22% |
| 2018 | 2018-12-31 | £1.9M | £949,000 | +95.96% |
| 2017 | 2017-12-31 | £989,000 | −£334,000 | −25.25% |
| 2016 | 2016-12-31 | £1.3M | −£52,000 | −3.78% |
| 2015 | 2015-12-31 | £1.4M | — | — |
Biodexa Pharmaceuticals revenue growth trends
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...
